BRIEF-Lilly Receives Additional FDA Approval For Verzeniotm, As Initial Treatment For Advanced Breast Cancer [Reuters]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Reuters
BRIEF-Lilly Receives Additional FDA Approval For Verzeniotm, As Initial Treatment For Advanced Breast Cancer | Reuters Reuters Staff 1 Min Read Feb 26 (Reuters) - Eli Lilly And Co: * LILLY RECEIVES ADDITIONAL FDA APPROVAL FOR VERZENIOTM (ABEMACICLIB), AS INITIAL TREATMENT FOR ADVANCED BREAST CANCER * ELI LILLY AND CO - ?NEW INDICATION BASED ON MONARCH 3 TRIAL CAN HELP MORE WOMEN LIVING WITH HR+, HER2- ADVANCED BREAST CANCER * ELI LILLY - ?RECOMMENDED DOSE OF VERZENIO IN COMBINATION WITH AI IS 150 MG ORALLY TWICE DAILY, CONTINUED UNTIL DISEASE PROGRESSION/ UNACCEPTABLE TOXICITY * ELI LILLY AND CO - ?VERZENIO IS AVAILABLE IN 4 TABLET STRENGTHS (200 MG, 150 MG, 100 MG, AND 50 MG)? Source text for Eikon: Further company coverage: All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. © 2018 Reuters. All Rights Reserved. BRIEF-Lilly Receives Additional FDA Approval For Verzeniotm, As Initial Treatment For Advanced Breast Cancer Feb 26 (Re
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- American College Of Physicians Officially Recommends GLP-1s Like Ozempic For Diabetes Treatment—Despite Shortage Concerns [Forbes]Forbes
- Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data [Yahoo! Finance]Yahoo! Finance
- Corticosteroids Market Size Expected to Reach USD 6.91 Bn by 2033 [Yahoo! Finance]Yahoo! Finance
- As Zepbound shortage grows, Eli Lilly says there's no immediate end in sight [MSNBC.com]MSNBC.com
- The Zacks Analyst Blog Highlights Eli Lilly, Linde, Caterpillar, Salesforce, and Wells Fargo [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/6/24 - Miss
LLY
Sec Filings
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- LLY's page on the SEC website